Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025
Rhea-AI Summary
Rein Therapeutics (NASDAQ: RNTX), a biopharmaceutical company focused on developing first-in-class medicines for orphan pulmonary and fibrosis conditions, has announced its upcoming presentation at The Citizens Life Sciences Conference 2025.
Brian Windsor, Ph.D., who serves as President and Chief Executive Officer, will deliver the presentation on Thursday, May 8, 2025 at 12:00 p.m. EDT in New York, NY.
Interested parties can access the presentation through a live webcast at the company's investor relations website. The recording will remain available for 90 days after the event.
Positive
- Company is developing first-in-class medicines for orphan pulmonary and fibrosis indications, targeting potentially lucrative niche markets
Negative
- None.
News Market Reaction – RNTX
In the trading session that priced this news, RNTX declined 4.09%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the event can be accessed at https://ir.reintx.com/events-presentations. A replay of the webcast will be available for 90 days following the presentation.
About Rein Therapeutics
Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. A Phase 2 clinical trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis is anticipated to be initiated in the first half of this year. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the
Rein Investor Relations & Media Contact:
Argot Partners
rein@argotpartners.com
212-600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/rein-therapeutics-to-present-at-the-citizens-life-sciences-conference-2025-302443270.html
SOURCE Rein Therapeutics, Inc.